Q99MW3 AF NFT

Preferentially expressed antigen in melanoma-like protein 1

MOLNFT AF v1 smart contract in GenesisL1 blockchain:

0xBf7491af3407816DFa88a5EA4c82e8A2B1D721eD

IPFS of NFT metadata:

bafybeig4xcw3ptd2rmwlxpkav5ccems3m67tmnsgtppnuv7hfs2cf6stru/metadata.json

IPFS of structure file:

bafybeibx5pem4ot6v7dato4gmcsftqmvfkqydr4pnfz67hxhbrbxy6bsiu/AF-Q99MW3-F1-model_v2.pdb

First NFT owner address (eip-55):

0x727cbC102994D358db33926fa99796E8d5d62fE1

First NFT owner address (bech32):

genesis1wf7tcypfjnf43kenjfh6n9ukar2avtlpffhgwn

Current NFT ID #308203 owner (web3):

0x14905748151782814d1AA807Ec0342Dd8879634b

First owner GALLERY | EVM EXPLORER | COSMOS EXPLORER

MOLNFT AF v1_w

NFT id:
308203
Accession (UniProt):
Q99MW3
Name::
Preferentially expressed antigen in melanoma-like protein 1
Experimental Method:
Predicted structure
Sequence source:
MUS MUSCULUS

NFT data

MolNFT AF v1 is an AlphaFold database of AI predicted Swiss-Prot protein sequences preserved as regular ERC-721 NFT tokens on GenesisL1 blockchain for public free use, research and entertainment:

https://alphafold.ebi.ac.uk/
Jumper, J., Evans, R., Pritzel, A. et al. Highly accurate protein structure prediction with AlphaFold. 
Nature 596, 583–589 (2021). https://doi.org/10.1038/s41586-021-03819-2

MOLNFT Q99MW3 research and analysis (ICN3D with VR)

FASTA sequences

>sp|Q99MW3|PRAL1_MOUSE Preferentially expressed antigen in melanoma-like protein 1 OS=Mus musculus OX=10090 GN=Pramel1 PE=1 SV=1 MSCKTPPTLQELAENSLLKNQDLAISALDDIPSLFFPSLFKKACRNRYVGIIKAMVQAWPFPCLPLGAMISRKTAYRRILEIILYGLDALLSQKVPHSRCKLQVLDLRVMPLKLWNRLPVFGTAGCSENPAVVGHSGTEVKQPVKVLVDLVLKESPLDSTESFLVQWVDNRNGLVSLCCCKLQIWAMSMYYHRKLLEILDLDSVQELRMYCISNPVCLLNFAPYLGRMRNLRCLILSHLWQTFSMTPVEKQQVITQFTSQFLKLKCLQILHLDTVFFLEGHLDELFWWLKTPLETLSVIDCNLSKSDWFHISEFQCTSQLKHLNLKWVKLTHLSPEPLRVLLLKSASTLTSLDLEGCQMMDSQLSAILPALRCCTQLTKFNFHGNYISMPILRELAYNVVKQKSQQSKIRFIPSCSHHSGLEFEAISQPHIVFVDVDRTTGEQEQVLFYAICSGEYVL

MOLNFT AF v1_w

NFT data

MOLNFT Q99MW3 research and analysis (ICN3D with VR)

FASTA sequences

We use cookies on this site to enhance your user experience